JPRN-UMIN000017320已完成2 期
A randomized phase II study to assess the efficacy of acid blocker on prevention of hemorrhage and healing of ulcers after endoscopic submucosal dissection(ESD) for gastric neoplasms - PCAB study
Osaka Medical Center for Cancer and Cardiovascular Diseases0 个研究点目标入组 140 人开始时间: 2015年4月30日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) History of gastrectomy or reconstruction of gastric tube. 2) History of radiation therapy to the upper abdominal region. 3) Undifferentiated-type cancer 4) Schedule of endoscopic treatment for esophageal or duodenal lesion concurrently. 5) History of endoscopic treatment for upper GI lesion in the past 28 days. 6) Schedule of endoscopic treatment for upper GI lesion within 28 days after the gastric ESD. 7) Allergy to vonoprazan and lansoprazole. 8) Systemic administration (intravenously or orally) of either one or more drugs of corticosteroid, anticoagulant agent or antiplatelet agent. 9) Systemic administration of non-steroid anti-inflammatory drug which cannot be suspended through 7 days before to 28 days after gastric ESD. 10) Pregnant or lactation woman. 11) Diagnosis of psychiatric diseases. 12) With active bacterial or fungus infection. 13) History of myocardial infarction or unstable angina pectoris within 3 months. 14) With uncontrollable hypertension. 15) With severe respiratory disease requiring continuous oxygen therapy.
研究者
相似试验
进行中（未招募）
1 期
FOLFIRI + panitumumab in second-line in subjects with wild type RAS metastatic colorectal cancer who have received FOLFOX + panitumumab in first-lineEUCTR2017-004519-38-ESGrupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD85
招募中
2 期
A randomized phase 2 study assessing the efficacy and safety of levofloxacin added to the GEM/nabPTX combination therapy in patients with advanced pancreatic cancer(T-CORE2201)pancretic cancerJPRN-jRCTs021230005Ishioka Chikashi140
进行中（未招募）
1 期
A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and Homologous Recombination Deficiency (HRD) (GeparOla)EUCTR2015-003509-41-DEGBG Forschungs GmbH106
进行中（未招募）
1 期
Phase II study of Panitunumab plus Cetuximab in pretreated in patients with metastatic colorectal cancermCRCMedDRA version: 20.0Level: HLGTClassification code 10017991Term: Gastrointestinal neoplasms malignant and unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001600-12-ITDipartimento di Medicina di Precisione - Università degli studi della Campania L. Vanvitelli112
招募中
2 期
A randomized phase II study to evaluate efficacy of negative pressure wound therapy on prophylaxis of the incisional hernia after reversal of temporaly diverting stomatemporally diverting stoma to be planned to have closedJPRN-UMIN000030936Aichi Medical University70